On the Record · Bio-techne
Bio-techne acquisitions, on the record
The businesses Bio-techne bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Lunaphore SA (Lunaphore)Word for word“As disclosed in Note 4, the Company completed the acquisition of Lunaphore for $169.7 million, in a cash-free, debt-free acquisition.” 10-K for 2024 | acquisition | — | $169.7 million |
NamocellWord for word“During fiscal year 2023, the Company acquired Namocell for $101.2 million, net of cash acquired.” 10-K for 2024 | acquisition | during fiscal year 2023 | $101.2 million, net of cash acquired |
Changzhou Eminence Biotechnology Co., Ltd. (Eminence)Word for word“During the first fiscal quarter of 2023, the Company sold its remaining shares in Eminence, its partially-owned consolidated subsidiary, for $17.8 million.” 10-K for 2024 | divestiture | during the first fiscal quarter of 2023 | $17.8 million |
Wilson Wolf Corporation (remaining 80.1% ownership)Word for word“Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, which requires the Company to acquire the remaining 80.1% of Wilson Wolf on December 31, 2027.” 10-K for 2024 | agreed acquisition | on December 31, 2027 | — |
Wilson Wolf Corporation (Wilson Wolf)Word for word“During fiscal 2023, Wilson Wolf met the EBITDA target and the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf.” 10-K for 2025 | acquisition | fiscal 2023 | $232 million |
Disposal group in the Protein Sciences segment (business held-for-sale)Word for word“During the second quarter of fiscal 2024, as part of restructuring actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023.” 10-K for 2025 | divestiture | as of December 31, 2023 | — |
Disposal group in the Diagnostics and Spatial Biology segment (business held-for-sale)Word for word“During the fourth quarter of fiscal 2025, as part of restructuring actions, certain assets and liabilities associated with a disposal group in our Diagnostics and Spatial Biology segment were classified as held-for-sale as of May 31, 2025.” 10-K for 2025 | divestiture | as of May 31, 2025 | — |
Partially-owned consolidated subsidiaryWord for word“Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.” 10-K for 2025 | divestiture | first fiscal quarter of 2023 | — |
Lunaphore SAWord for word“As disclosed in Note 4, the Company completed the acquisition of Lunaphore in fiscal 2024 for $169.7 million, in a cash-free, debt-free acquisition.” 10-K for 2026 | acquisition | in fiscal 2024 | $169.7 million |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-06-30 | $91.4 million | $49.5 million |
| 2017-06-30 | $253.8 million | $147.5 million |
| 2018-06-30 | $67.9 million | $19.1 million |
| 2019-06-30 | $289.5 million | $136.3 million |
| 2020-06-30 | $0 | — |
| 2021-06-30 | $225.4 million | $102.8 million |
| 2023-06-30 | $101.2 million | $51.3 million |
| 2024-06-30 | $169.7 million | $104.7 million |
Deal filings since 2016
- 2026-06-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-09-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2018-06-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-10-14 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2016-08-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2016-07-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Bio-techne’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-08-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.